Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule

Table 2

Whom to screen.

---

Lp(a) should be measured once in all subjects at intermediate or high risk of CVD/CHD who present with one of the following:

 (i) Premature CVD

 (ii) Recurrent CVD despite statin treatment

 (iii) Familial hypercholesterolemia

 (iv) Strong family history of premature CVD and/or elevated Lp(a) ≥500 mg/L

 (v) Recurrent CVD despite optimal lipid-lowering treatment

 (vi) ≥5% 10-year risk of fetal CVD according to European guidelines

 (vii) ≥10% 10-year risk of fetal CVD according to US guidelines

 (viii) 10–19% Framingham risk according to the 2012 Canadian Cardiovascular Society recommendations

Repeat measurement is only necessary if treatment for high Lp(a) levels is initiated in order to evaluate therapeutic response

---

This table was adopted from [194].